相关实验视频

Updated: Sep 12, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

设计,合成和生物活性新强效的型素衍生物的设计,合成和生物活性

Zhun Li¹, Danqian Ma¹, Chang Liu¹

¹Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.

European journal of medicinal chemistry

|August 5, 2025

概括

新的pleuromutilin衍生物可以对抗抗生素耐药性. 衍生品4g显示强大的抗菌活性对抗格拉姆阳性细菌,超越现有的药物和证明低毒性.

科学领域:

药用化学医学化学
抗微生物耐药性研究研究
药物发现药物发现药物发现

背景情况:

过度使用抗生素加速了细菌的耐药性,降低了当前治疗的有效性.
耐药细菌对全球健康构成重大威胁,需要新型治疗剂.
斑红素衍生物是一种抗生素类,具有对抗耐药菌株的潜力.

研究的目的:

设计和合成新型二甲基半胺 Pleuromutilin衍生物.
评估这些衍生物的体外和体外抗菌活性.
确定开发新抗菌疗法的有前途的候选人.

主要方法:

合成了一系列二甲基半胺斑素衍生物.
在体外抗菌测定以确定最小抑制度 (MIC).
在体内疗效研究,抗生素后效应 (PAE) 分析,耐药性发展评估,细胞毒性和急性毒性测试 (LD50).
分子对接和抑制绿色光蛋白 (GFP) 在细菌中的表达.

主要成果:

大多数衍生品表现出对格拉姆阳性细菌的强烈活性,超过了 tiamulin 的活性.
衍生品4g表现出异常的抗菌活性 (MIC低至0.016μg/mL) 和优异的后抗生素效应 (PAE) 与 tiamulin 相比.
衍生4g显示出抗性发展的速度较慢,出色的分子对接结果,并有效地抑制了GFP表达.
衍生品4g显示出非常低的细胞毒性和低的口服急性毒性 (LD50>2000 mg/kg).
衍生品4g被证明比 tiamulin 和 valnemulin 对抗抗甲素耐药黄金葡萄球菌 (MRSA) 感染更有效.

结论:

衍生4g是一种非常有前途的化合物,具有强大的广泛抗菌活性和有利的安全性.
衍生4g具有显著的潜力,用于开发针对耐药细菌感染的新疗法.
合成的плеуромутилин衍生物代表了对抗抗菌素耐药性的宝贵补充.

关键词:

具有抗菌活性,具有抗菌活性.狄米甲基囊胺的使用方法在MRSA中,MRSA可能是MRSA.性肌肉素是如何形成的有毒性有毒性

更多相关视频

From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028

From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028

Published on: January 13, 2017

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

相关概念视频

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...